查詢結果分析
相關文獻
- Clinical Assessment of Women Undergoing In-Vitro Fertilization and Tubal Embryo Transfer Using Recombinant Human Follicle-Stimulating Hormone
- 子宮內膜異位症家族傾向調查報告
- 子宮內膜異位症
- 子宮內膜異位症與CA-125
- The Different Effects of Peritoneal Fluid Protein in the Follicular and Luteal Phase from Cases of Nonendometriosis on the in Vitro Development of Two-Cell Mouse Embryos
- 漫談子宮內膜異位症及治療
- 子宮內膜異位症的一般概念
- 子宮內膜異位症
- 子宮內膜異位症診斷與治療
- 子宮內膜異位症合併不孕症的治療
頁籤選單縮合
題 名 | Clinical Assessment of Women Undergoing In-Vitro Fertilization and Tubal Embryo Transfer Using Recombinant Human Follicle-Stimulating Hormone=體外受精與輸卵管胚胎植入的婦女使用基因合成人類濾泡刺激素的臨床評估 |
---|---|
作 者 | 趙光漢; 楊政憲; 陳欽德; 吳明義; 何弘能; 楊友仕; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷 期 | 38:4 1999.12[民88.12] |
頁 次 | 頁121-130 |
分類號 | 417.125 |
關鍵詞 | 基因合成人類濾泡刺激素; 尿液提煉人類濾泡刺激素; 不明原因不孕症; 子宮內膜異位症; Recombinant FSH; Urinary FSH; Unexplained infertility; Endometriosis; |
語 文 | 英文(English) |
中文摘要 | 目的:本研究想比較體外受精與輸卵管胚胎植入的不孕症婦女使用基因合成或尿液提煉人類濾泡刺激素,來刺激卵巢濾泡發育的效果與安全性。 方法:把40位年齡27歲到38歲患有不明原因不孕症或輕微子宮內膜異位的不孕婦女,任意分為兩組。事先給予buserelin acetate,然後分別以基因合成或尿液提煉人類濾泡刺激素刺激濾泡發育,並以每天300 IU為起始劑量。在注射hCG後,實施標準的體外受精與輸卵管胚胎植入。最後測量濾泡發育情形、取卵數、受精率、人類濾泡刺激素使用時間與劑量和懷孕率等變數。 結果:人類濾泡刺激素治療期間濾泡發育與成長的情形,包括大於10mm和大於14mm的濾泡平均數目,兩組很類似。人類濾泡刺激素的使用期間(基因合成組:9.8 ± 2.1天;尿液提煉組:9.0 ± 1.7天) 與平均劑量(基因合成組:2224 ± 715IU;尿液提煉組:2118 ±513IU)也相近。hCG注射日的雌二醇濃度(基因合成組:1732.9 ± 1279.3pg/mL:尿液提煉組:1792.3 ± 1194.8pg/mL) 與卵巢inhibin濃度(基因合成組:8.6 ± 5.6U/mL:尿液提煉組:8.3 ± 4.8U/mL)兩組地無差別。在基因合成組有十位病人臨床懷孕;而尿液提煉組有九位懷孕。此外,在安全性和副作用上兩組地無差異。 結論:此臨床研究顯示基因合成的人類濾泡刺激素在刺激卵巢濾泡發育上,與尿液提煉約有相似安全性與療效。 |
英文摘要 | OBJECTIVE: To compare the efficacy and safety of a recombinant human follicle-stimulating hormone (hFSH) preparation with a urinary hFSH preparation for stimulating follicular development in infertile women undergoing in vitro fertilization and embryo transfer. METHODS: Forty infertile women aged 27 to 38 years suffering from unexplained infertility or mild endometriosis were randomized into two groups in the prospective open, parallel group clinical study. The eligible subjects were pretreated with buserelin acetate, followed by recombinant or urinary hFSH treatment started at an initial dose of 300 tU FSH/day. After administration of hCG, a standard IVF-TET (in vitro fertilization and tubal embryo transfer) procedure was performed. Several main parameters, including follicular development, oocyte retrieval, number of fertilized oocytes, duration and dosage of FSH, and occurrence of pregnancy, were evaluated. RESULTS: Twenty patients were treated with recombinant hFSH and 20 with urinary hFSH. The dynamics of follicular recruitment and growth during FSH treatment were found to be similar in both treatment groups regarding the mean number of follicles >10 mm and the mean number of > 14 mm in diameter on the day of hCG administration. The duration of FSH treatment to achieve full follicular development was very similar (9.8 ± 2.1 and 9.0 ± 1.7 days, for recombinant and urinary hFSH, respectively), as was the average dose of FSH to reach this stage (2224 ± 715 and 2118 ± 513 IU of FSH, for recombinant and urinary hFSH, respectively). On the day of hCG administration, the estradiol (E��) levels were 1732.9 ± 1279.3 and 1792.3 ± 1194.8 pg/mL for recombinant and urinary hFSH, respectively, and there were still no differences in the ovarian inhibin outputs, 8.6 ± 5.6 and 8.3 ± 4.8 U/mL, respectively. Ten clinical pregnancies were recorded in the recombinant hFSH group and nine in the urinary hFSH group. In terms of safety, no difference was recorded between the groups. CONCLUSION: This clinical study shows that recombinant hFSH has similar safety and effectiveness as compared with urinary hFSH in stimulating ovarian follicular development. |
本系統中英文摘要資訊取自各篇刊載內容。